EGFR and non-small cell lung carcinoma: In NSCLC cell lines, geftinib‐derived EGFRL858R‐targeting PROTAC effectively reduced EGFR targeting signaling in a dose‐dependent manner and showed minimal cytotoxicity against wild‐type EGFR (Cheng, Yu, et al. 2020).